Acadian Asset Management
XENE icon

Acadian Asset Management’s Xenon Pharmaceuticals XENE Stock Holding History

Acadian Asset Management’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-677
Closed -$39K – 2274
2026
Q1 		$39K Buy
+677
New +$31.2K ﹤0.01% 1884
2021
Q3 		– Sell
-2,365
Closed -$44K – 2053
2021
Q2 		$44K Sell
2,365
-24,288
-91% -$448K ﹤0.01% 1821
2021
Q1 		$476K Sell
26,653
-50,705
-66% -$859K ﹤0.01% 1214
2020
Q4 		$1.19M Sell
77,358
-5,359
-6% -$62.7K ﹤0.01% 934
2020
Q3 		$915K Buy
82,717
+21,789
+36% +$256K ﹤0.01% 939
2020
Q2 		$762K Buy
60,928
+55,244
+972% +$703K ﹤0.01% 1052
2020
Q1 		$64K Buy
+5,684
New +$80.9K ﹤0.01% 1455
2015
Q4 		– Sell
-10,474
Closed -$86K – 1522
2015
Q3 		$86K Sell
10,474
-11,652
-53% -$116K ﹤0.01% 1006
2015
Q2 		$255K Buy
22,126
+18,237
+469% +$252K ﹤0.01% 896
2015
Q1 		$65K Buy
3,889
+308
+9% +$5.69K ﹤0.01% 1064
2014
Q4 		$71K Buy
+3,581
New +$52.6K ﹤0.01% 1034

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Acadian Asset Management's XENE Position: Q2 2026 in Review

Acadian Asset Management sold out of Xenon Pharmaceuticals (XENE) in Q2 2026, closing a stake of 677 shares — an estimated $39K sold.

Acadian Asset Management first reported a position in XENE in Q4 2014 and held it in 11 quarters. The position peaked at $1.19M in Q4 2020. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • Acadian Asset Management reported no remaining Xenon Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Acadian Asset Management sold 677 Xenon Pharmaceuticals shares in Q2 2026, an estimated $39K.
  • Acadian Asset Management first reported a position in Xenon Pharmaceuticals in Q4 2014 and held it in 11 quarters.
  • Acadian Asset Management's Xenon Pharmaceuticals position peaked at $1.19M in Q4 2020.
  • 315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.